Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BY002 in Relapsed or Refractory Acute Leukemia
NCT07270770Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BY002 in acute leukemia, sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Incidence of dose-limiting toxicities at Day 42 and Incidence of serious adverse events. Started Mar 2026; status: recruiting.
02
Drugs
BY002
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT07270770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270770.